![Ellen Rohde](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ellen Rohde formerly worked at Biogen, Inc., as Associate Director, Cerulean Pharma, Inc., as Director-Analytical Chemistry & DMPK, Intellia Therapeutics, Inc., as Senior Director-Pharmacokinetics, and Verve Therapeutics, Inc., as VP-Preclinical Pharmacology & Toxicology from 2019 to 2025.
Dr. Rohde received her doctorate degree from the University of Cincinnati (Ohio) and graduate degree from Universität Leipzig.
| Unternehmen | Position | Ende |
|---|---|---|
| VERE THER | Corporate Officer/Principal | 25.07.2025 |
| BIOGEN INC. | Corporate Officer/Principal | - |
Cerulean Pharma, Inc.
 Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Design and develops nanopharmaceuticals | Corporate Officer/Principal | - |
| INTELLIA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 6 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
University of Cincinnati (Ohio)
 University of Cincinnati (Ohio) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Universität Leipzig
 Universität Leipzig Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Design and develops nanopharmaceuticals | Health Technology |
Intellia Therapeutics, Inc.
 Intellia Therapeutics, Inc. BiotechnologyHealth Technology Develops novel and potentially curative therapeutics | Health Technology |
Verve Therapeutics, Inc.
 Verve Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines to treat patients with cardiovascular disease | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
